Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib with Carotuximab in Advanced EGFR-mutated NSCLC
NCT05401110Phase 1Recruiting
- Start
- Sep 2023
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carotuximab in non-small cell lung cancer (NSCLC). Primary endpoint: Number of adverse events and dose-limiting toxicities at 4 weeks. Started Sep 2023; status: recruiting.
02
Drugs
carotuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05401110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05401110.